U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07337395) titled 'Proteomic Changes in Patients With Myasthenia Gravis and Ravulizumab' on Dec. 19, 2025.
Brief Summary: Myasthenia gravis (MG) is an autoimmune neuromuscular disorder primarily caused by antibodies targeting postsynaptic components of the neuromuscular junction, most commonly the acetylcholine receptor (AChR). In AChR-positive generalized MG, IgG1 and IgG3 antibodies activate the classical complement pathway, leading to membrane attack complex-mediated damage of the postsynaptic membrane and impaired neuromuscular transmission. Complement inhibition has therefore emerged as an effective therapeutic strategy.
Ravulizumab, a long-acti...